Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study
نویسندگان
چکیده
منابع مشابه
Phase II Study of Irinotecan plus S-1 in Treatment of Advanced Gastric Cancer
Objective: The efficacy and safety of irinotecan hydrochloride (CPT-11) plus oral fluoropyrimidine S-1 combination therapy in patients with previously untreated advanced gastric cancer was evaluated. Methods: The regimen comprised CPT-11 plus S-1: CPT-11, 60 mg/m (days 1, 15); S-1, 40 60 mg/body twice daily (days 1 21) followed by a 1-week rest, every 4 weeks. Primary endpoint was response rate...
متن کاملFeasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
BACKGROUND Gastric cancer with cancer cells on peritoneal cytology has very poor prognosis because of the existence of simultaneous peritoneal metastasis. Here we performed a dose-escalation study of intraperitoneal docetaxel (DTX) combined with S-1 to determine the maximum-tolerated dose (MTD) and recommended dose (RD) in gastric cancer with peritoneal dissemination. PATIENTS AND METHODS Twe...
متن کاملFeasibility of Outpatient Chemotherapy with S-1 and Cisplatin for Gastric Cancer
Objective: To evaluate the feasibility of S-1 and high-dose cisplatin short hydration regimens for outpatients with unresectable metastatic gastric cancer. Methods: Data for individual outpatients treated in our institution were retrospectively pooled to assess the feasibility of an S-1 and highdose cisplatin short hydration regimen (S-1: 80 to 120 mg on Days 1 to 21; cisplatin: 60 mg/m2 on Day...
متن کاملFeasibility and efficacy of combination chemotherapy with S-1 and fractional Cisplatin for advanced gastric cancer.
BACKGROUND There is a great need for effective outpatient chemotherapy for advanced gastric cancer in patients with good performance status. The present pilot study evaluated the use of combination chemotherapy with S-1 and fractional CDDP for unresectable-recurrent gastric cancer in an outpatient setting. PATIENTS AND METHODS A total of 41 patients with unresectable or recurrent gastric canc...
متن کاملPhase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
OBJECTIVE A dose-escalation study of irinotecan (CPT-11) combined with S-1, a novel oral fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLTs) in advanced gastric cancer. METHODS S-1 was administered orally at 80 mg/m(2)/day for 21 consecutive days followed by a 2 week rest. CPT-11 was given intravenously on da...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Letters
سال: 2011
ISSN: 1792-1074,1792-1082
DOI: 10.3892/ol.2011.435